Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 6, 1997, Pages 375-384

  Safavy, Ahmad ^a   Khazaeli, M B ^b   Mayo, Matthew S ^b   Buchsbaum, Donald J ^a  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENOL DERIVATIVE; RHENIUM 188;

ANIMAL EXPERIMENT; ARTICLE; CANCER; COLON CANCER; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

EID: 0031436018     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.375     Document Type: Article

References (36)

1. Buchsbaum DJ, Langmuir VK and Wessels BW. Experimental radioimmunotherapy. Med Phys 1993; 20:551-567.
2. Yarranton G. Antibodies as carriers for drugs and radioisotopers, In: Antibody Therapeutics, Boca Raton, CRC Press, 1997:53.
3. Buchsbaum DJ. Experimental radioimmunotherapy and methods to increase therapeutic efficacy, In: Cancer Therapy with Radiolabeled Antibodies, Boca Raton, CRC Press, 1995:115-140.
4. Engler D and Burger AG. The deiodination of the iodotyrosines and of their derivatives in man. Endoc Rev 1984;5:151.
5. Mattes MJ, Griffiuis GL, Diril H, Goldenberg DM, Ong GL and Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73:787.
6. Mather SJ and Ellison D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med 1990;31:692.
7. Sykes TR, Woo TK, Baum RP, Qi P and Noujaim AA. Direct labeling of monoclonal antibodies with technetium-99m by photoactivation. J Nucl Med 1995; 36:1913.
8. Griffiths GL, Goldenberg DM, Knapp FF, Jr., Callahan AP and Chang C-H. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: Labeling and animal biodistribution studies. Cancer Res 1991;51:4594-4602.
9. Srivastava SC and Mease RC. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. Nucl Med Biol 1991;18:589-603.
10. 186Re-labeling of monoclonal antibodies. Cancer 1994;73:769-773
11. 99mTc-protern conjugates. Bioconjugate Chem 1991;2.333-336.
12. Brechbiel MW, Gansow OA, Atcher RW, Schlom J, Esteban J, Simpson DE and Colcher D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA: Antibody labeling and tumor-imaging studies. Inorg Chem 1986;25:2772-2781.
13. Ali MS and Quadri SM. Maleimido derivatives of diethylenetriaminepentaacetic acid and triethylenetetramine-hexaacetic acid: Their synthesis and potential for specific conjugation with biomolecules. Bioconjugate Chem 1996;7:576.
14. Parker D. Tumor targeting with radiolabeled macrocycle-antibody conjugates. Chem Soc Rev 1990;19:271.
15. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, Salako QA and Meares CF. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates Cancer (Suppl) 1994;73:779.
16. Novak-Hofer I, Amstutz HP, Macke HR, Schwarzbach R, Zimmermann K, Morgenthaler J-J and Schubiger PA. Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells. Cancer Res 1995;55:46-50.
17. Prakash S, Went MJ and Blower PJ. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Nucl Med Biol 1996; 23:543.
18. Fritzberg AR, Abrams PG, Beaumier PL, Kasina S, Morgan AC, Rao TN, Reno JM, Sanderson JA, Srinivasan A, Wilbur DS and Vanderheyden JL. Specific and stable labeling of antibodies with technetium-99m with a diamide dithiolate chelating agent. Proc Nat Acad Sci USA 1988;85:4025-4029.
19. Breitz HB, Weiden PL, Vanderheyden J-L, Appelbaum JW, Bjom MJ,Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC, Fisher DR, Schroff RW, Fritzberg AR and Abrams PG. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: Results of phase I trials. J Nucl Med 1992; 33:1099-1112.
20. Safavy A, Buchsbaum DJ and Khazaeli MB. Synthesis of N-[tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl] methyl]succinamic acid, trisuccin. Hydroxamic acid derivatives as a new class of bifunctional chelating agents. Bioconjugate Chem 1993;4.194-198.
21. Gagliardi E and Raber H. Hydroxamsauren als analytische reagentien. Monatch Chem 1962;93: 360-368.
22. Ryser JE, Jones RML, Egeli R, Pelegrin A, Rose K, Kurt AM, Perin M, Broquet PE, Ambrosetti P, Fisch I, Pochon S, Donath A, Mach JP and Offord RE. Colon carcinoma immunoscintigraphy by monoclonal anti-CEA antibody labeled with gallium-67-aminooxyacetyl deferroxamine. J Nucl Med 1992;33:1766.
23. Word MC, Roberts KR, Westwood JH, Coombes RCC and McCready VR. The effect of chelating agents on the distribution of monoclonal antibodies in mice. J Nucl Med 1986 ;27:1746.
24. Safavy A, Khazaeli MB and Buchsbaum DJ. Rhenium-186 labeling of CC49 monoclonal antibody with N-[tris[2-[[N-benzyloxy)amino]carbonyl]ethyl]meth yl]succinamic acid, trisuccin, and biodistribution studies. J Nucl Med 1994;35:258P-259P.
25. Muraro R, Kuroki M, Wunderlich D, Poole DJ, Colcher D, Thor A, Greiner JW, Simpson JF, Molinolo A, Noguchi P and Schlom J. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988;48:4588-4596.
26. 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1990; 18:1033-1041.
27. Safavy A, Sanders A, Qin H and Buchsbaum DJ. Conjugation 6 of unprotected trisuccin, AT-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol Bioconj Chem 1997; 8:766-771.
28. Lindmo T, Boven E, Cuttitta F, Fedorko J and Bunn J.P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
29. Paik CH, Yokoyama K, Reynolds JC, Quadri SM, Min CY, Shin SY, Maloney PJ, Larson SM and Reba RC. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor. Journal of Nuclear Medicine 1989;30:1693-701.
30. Arano Y, Matsushima H, Tagawa M, Koizumi M, Endo K, Konishi J and Yokoyama A. A novel bifunctional metabolizable linker for the conjugation of antibodies with radionuclides. Bioconjugate Chemistry 1991;2 71-6.
31. Quadri SM, Vriesendorp HM, Leichner PK and Williams JR. Evaluation of indium-III- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 1993;34:938-945.
32. A.
33. Arano Y, Wakisaka K, Mukai T, Uezono T, Motonari H, Akizawa H, Kairiyama C, Ohmomo Y, Tanaka C, Ishiyama M, Sakahara H, Konishi J and Yokoyama A. Stability of a metabolizable ester bond in radioimmunoconjugates. Nuclear Medicine and Biology 1996; 23:129-136.
34. Studer M, Kroger LA, DeNardo SJ, Kukis DL and Meares CF. Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo. Bioconjugate Chem 1992,3:424-429.
35. 99mTc-radiolabeled antibody Fab'-chelator conjugate. Bioconjugate Chem 1990;1:431-437.
36. Heymann E. Hydrolysis of carboxylic ester and amides, In-Metabolic basis of detoxification: Metabolism of functional groups, New York, Academic Press, 1982:229-241.